Ipamorelin vs Sermorelin

Before anything else: the dataset lists Ipamorelin and Sermorelin in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.

Both are classed here as growth hormone secretagogues, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is recovery and sleep and muscle growth. On this site's goal weighting — an editorial priority score, not a measure of effect size — Ipamorelin rates 4/5 for recovery and sleep and Sermorelin rates 4/5.

This is the part that decides most of it. Sermorelin has approval from a regulator somewhere, though not a current FDA or EMA label — it was FDA approved as Geref, then withdrawn for commercial reasons. Ipamorelin has some human data, but it is small, old, or uncontrolled — small early-phase work only; development was discontinued. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

The kinetics are roughly 10× apart — 2 h for Ipamorelin against 12 min for Sermorelin — and yet both are dosed once daily. That schedule is convention rather than clearance, which is worth knowing before you assume the two behave the same way between doses.